Next Article in Journal
The Unique Light-Harvesting System of the Algal Phycobilisome: Structure, Assembly Components, and Functions
Next Article in Special Issue
Monocytes in the Characterization of Pain in Palliative Patients with Severe Dementia—A Pilot Study
Previous Article in Journal
Atherosclerotic and Cardio-Metabolic Diseases: From Molecular Basis to Therapeutic Advances
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 11
10.3390/ijms24119736
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Targeted Mass Spectrometry Approach to Identify Peripheral Changes in Metabolic Pathways of Patients with Alzheimer’s Disease

by
Pierluigi Reveglia
1,†,‡,
Carmela Paolillo
1,†,
Antonella Angiolillo
2,*,
Gabriella Ferretti
3,
Ruggero Angelico
4,
Rossana Sirabella
3,
Gaetano Corso
1,
Carmela Matrone
3 and
Alfonso Di Costanzo
2
1
Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy
2
Centre for Research and Training in Medicine of Aging, Department of Medicine and Health Sciences “Vincenzo Tiberio”, University of Molise, 86100 Campobasso, Italy
3
Division of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, 80131 Naples, Italy
4
Department of Agriculture, Environmental and Food Sciences, University of Molise, 86100 Campobasso, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally.
‡
Current address: Institute for Sustainable Agriculture, CSIC, 14004 Córdoba, Spain.
Int. J. Mol. Sci. 2023, 24(11), 9736; https://doi.org/10.3390/ijms24119736
Submission received: 1 April 2023 / Revised: 20 May 2023 / Accepted: 2 June 2023 / Published: 4 June 2023
(This article belongs to the Special Issue Basic, Translational and Clinical Research on Dementia)
Browse Figures
Versions Notes

Abstract

:
Alzheimer’s disease (AD), a neurodegenerative disorder, is the most common cause of dementia in the elderly population. Since its original description, there has been intense debate regarding the factors that trigger its pathology. It is becoming apparent that AD is more than a brain disease and harms the whole-body metabolism. We analyzed 630 polar and apolar metabolites in the blood of 20 patients with AD and 20 healthy individuals, to determine whether the composition of plasma metabolites could offer additional indicators to evaluate any alterations in the metabolic pathways related to the illness. Multivariate statistical analysis showed that there were at least 25 significantly dysregulated metabolites in patients with AD compared with the controls. Two membrane lipid components, glycerophospholipids and ceramide, were upregulated, whereas glutamic acid, other phospholipids, and sphingolipids were downregulated. The data were analyzed using metabolite set enrichment analysis and pathway analysis using the KEGG library. The results showed that at least five pathways involved in the metabolism of polar compounds were dysregulated in patients with AD. Conversely, the lipid pathways did not show significant alterations. These results support the possibility of using metabolome analysis to understand alterations in the metabolic pathways related to AD pathophysiology.

1. Introduction

Alzheimer’s disease (AD) has been known, for more than 100 years, as a brain disease, characterized by the combined presence of extracellular amyloid plaques consisting of amyloid-β (Aβ) peptides and intraneuronal neurofibrillary tangles, both densely packed to form highly insoluble structures [1]. Over the last decade, it has been noted that other conditions are usually associated with AD, such as cardiovascular disease and metabolic syndrome [2,3]. Indeed, AD usually includes various comorbidities, such as obesity, diabetes, dyslipidemia, and hypertension, collectively merging with metabolic syndrome [4,5,6,7]. In addition, the high Aβ insolubility of senile plaques and meningovascular Aβ deposits and the fact that Aβ is derived from the transmembrane cleavage of an integral membrane protein, the amyloid precursor protein (APP), suggests that membrane composition may control APP localization and trafficking in neurons, thus predisposing APP to undergo β-or α secretase-mediated APP processing [8,9].
Recent progress in targeted liquid chromatography coupled with mass spectrometry (LC-MS), has facilitated the dynamic evaluation of thousands of metabolites, reflecting complex networks and pathways of downstream changes at the genomic, transcriptomic, and proteome levels [10].
Here, we examined the plasma metabolome composition using a validated metabolomics procedure in patients with AD and healthy controls to assess the disease-related alterations in the metabolic pathways. The ultimate goal was to strengthen our understanding of the role of specific metabolites that might cause further disorders in AD, and to design common strategies to prevent or control these disorders during disease progression.

2. Results

2.1. Demographics of Participants

The present study investigated the plasma samples from 20 control subjects and 20 patients with AD. The epidemiological characteristics of the enrolled patients are presented in Table 1.
The AD patients did not differ in age or sex, but had significantly reduced MMSE scores compared with those of controls (p < 2.86 × 10−12). Significant differences were also observed in the educational level, which was lower in patients with AD than in controls (p < 0.05).

2.2. Partial Least Squares Discriminant Analysis (PLS-DA) and Volcano Plot for Control and AD Subjects

A well-defined platform for mass spectrometry analysis developed by the Biocrates Life Science AG service was used to analyze the metabolomic profiles of the 20 AD and 20 control subjects.
Potential alterations in the concentration of the 630 analyzed metabolites were first explored via univariate and multivariate statistical analysis, using the MetaboAnalyst 5.0 statistical analysis module.
Figure 1 shows the results of PLS-DA. In particular, the 3D graph shows the percentage variability in the first three principal components (PC) between the patients with AD (red) and the healthy subjects (green) (Figure 1a). Patients with AD tend to have the first three components that separate them from the control subjects. The observed differences were attributable to significant differences between the concentrations of the metabolites represented in the variable importance in projection (VIP) scores (Figure 1b). Figure 1b shows that 18 of the top 25 metabolites were downregulated. Seventeen metabolites were significantly altered in the patients with AD (Figure 1c). These compounds belong to various classes of organic compounds: five sphingolipids, five amino acids, three phospholipids, two lipids, one organic acid, and one fatty acid derivative. The metabolites were represented based on fold-change values (log2 (FC)) and statistical significance (−log10 (p)). The graph shows that the main downregulated metabolites are those reported in the upper left quadrant, for example, glutamic acid, hydroxy sphingomyelin, octadecadienoate, and aspartic acid. Instead, ceramide (d18:1/24:1) appeared to be the only significantly upregulated metabolite, considering that phosphatidylcholines showed borderline variation.
Table 2 shows that most significant metabolites, with a VIP score higher than 1.7, a statistical significance (p-value) lower than 0.05, and a |log2FC| > 0.0: 15 were downregulated and only two were upregulated. The mean, standard deviation, standard error, range values, and 95% CI of the mean of the downregulated or/upregulated metabolites are reported in Supplementary Table S2 for comparisons between AD and controls. Pearson’s correlation analysis is reported in Supplementary Table S3.

2.3. MSEA and Pathway Analysis

After the exploratory analysis, the complete data matrix with the quantified 630 metabolites was submitted to the MetaboAnalyst 5.0 modules for enrichment analysis using the MSEA algorithm, and pathway analysis.
Quantitative analysis of the metabolic pathways enriched for the 630 metabolites was not statistically significant. Nevertheless, the pathways for the biosynthesis of unsaturated fatty acids and steroid hormones were the most enriched lipids in this study. Specifically, oleic, arachidonic, docosahexaenoic, and eicosapentaenoic acids were the most enriched lipids in unsaturated fatty acid biosynthesis, whereas dehydroepiandrosterone sulfate and cortisol were the most enriched lipids in steroid hormone biosynthesis. These results are shown in Figure 2 and Table 3.
Interestingly, eight metabolic pathways were significantly altered, and the metabolite hits for each pathway are shown in Figure 3 and Table 4. Among all the hits, L-glutamate and L-aspartate were found to be altered, which is consistent with the univariate and PLS-DA analyses reported in the previous section.

3. Discussion

There has been considerable speculation regarding factors besides tau protein and Aβ that may contribute to AD. Metabolic dysregulation has been reported in the brain and blood samples of patients [11,12,13,14,15]. Changes in the metabolome are detectable well before the overt clinical signs of AD and are retained as the disease progresses towards more advanced stages [16,17,18]. However, whether dysregulated metabolites play causative or modulating roles, or are by-products of AD, remains unclear. Here, we used a new and well-defined platform for mass spectrometry analysis developed by the Biocrates Life Science AG service to analyze the metabolomic profiles of 20 AD and 20 control subjects.
PLS-DA and volcano plot analysis are very useful for identifying the main components, even the latent ones, which can differentiate patients from the controls. Moreover, the PLS-DA algorithm should be regarded as just one building block in a series of steps used to develop a classification model, particularly when the study involves small sample sizes and large numbers of variables [19]. Therefore, we further investigated our data to evaluate their impact on the metabolic pathways. We, subsequently, analyzed the most significant variables, indicated by both the VIP score and volcano plot, using quantitative MSEA and pathway analysis for polar and nonpolar metabolites. The volcano plots and VIP analyses revealed an increase in the ceramide levels and a decrease in the glutamic acid levels. In this context, several other studies have reported changes in ceramide levels in the plasma of patients [20,21,22,23] or neurons in AD animal models [24,25,26]. Ceramides are precursors of sphingolipids, including sphingomyelins, gluco- and galactosyl ceramides, hexosylceramides, lactosylceramides, sphingosine, dihydrosphingosine, and dihydroceramides. The role of ceramides in AD might be consistent with their potent action as regulators of cell survival, triggering pro-apoptotic signaling pathways and leading to neurodegeneration [27]. Ceramides have also been linked to oxidative stress and mitochondrial dysfunction [28]. Alterations in the lipid raft, containing a large number of sterols (cholesterol) and sphingolipids (sphingomyelin and glycosphingolipids), have been described as being responsible for the proteolytic activities of α- or β-secretases on APP [29,30,31]. This provides a strong rationale for hypothesizing that issues with membrane restructuring may be an early cause of Aβ accumulation in the brain. Accordingly, APP trafficking into or out of lipid rafts depends on the lipid composition [15,32]. In AD neurons, owing to specific cellular signals, APP interacts with transducers or different effector proteins and accumulates in lipid raft fractions, where β- and y-secretases are mostly located and activate amyloidogenic processing [33,34,35]. Several studies have demonstrated that the dysregulation of biosynthesis, turnover, and remodeling of membrane sphingolipids promotes β peptide production and aggregation [15]. The β peptides directly disrupt the integrity of the lipid bilayer by interacting with sphingolipids [36].
In addition, alterations in the sphingolipid structure and composition affect phosphatase and tyrosine kinase activities [37,38], which are known to be altered in AD and other neurodegenerative diseases [39]. Notably, Fyn tyrosine kinase, which belongs to the Src family of protein tyrosine kinases (STKs), is an integral lipid raft protein widely expressed in the brain [39,40]. It is hyperactivated in AD and promotes either APP phosphorylation on Tyr682 [41] or Tau phosphorylation on Tyr18 [42]. In contrast, a significant reduction in plasma glutamic acid level was observed.
Glutamate is a non-essential amino acid that acts as an excitatory neurotransmitter or GABA precursor. The role of glutamate in cognitive aging and AD remains unclear, although its role in the regulation of learning and memory functions in the CNS is well recognized [43,44]. Indeed, glutamatergic synapses appear to be compromised in the AD brain, thus affecting cognition and behavior. A reduction in plasma glutamate levels was previously reported [45] and was proposed as a peripheral marker to identify patients with mild cognitive impairment (MCI) and AD [46]. A decrease in peripheral glutamate is likely paralleled by the accumulation of glutamate in the brain, with consequent neurotoxicity due to an increase in the entry of Ca2+ into the neurons [44]. Notably, Aβ peptides and oligomers are neurotoxic because they directly bind to glutamate receptors and activate downstream signaling, ultimately causing hyperexcitability [47,48]. Consistently, the NMDA partial antagonist, memantine, is believed to improve cognition, behavior, and global function in subjects with AD by reducing glutamate activity in the brain. Decreased glutamate levels have also been reported in the brains of patients with amnestic mild cognitive impairment (MCI), by proton magnetic resonance spectroscopy in vivo imaging (MRSI) [49]. Lin et al. reported higher L-glutamate levels in the blood of individuals with MCI and mild or moderately severe AD than in controls. In contrast, the same group showed that D-glutamate levels in the blood progressively decreased from the control to MCI, mild AD, and late-phase AD [50]. This reduction suggests that, at least in a subgroup of patients with AD, the pathogenic mechanism is characterized by an increased use of some ketogenic and/or glucogenic amino acids as an energy substrate. The carbon skeletons of ketogenic and/or glucogenic amino acids may be broken down into metabolites that enter the tricarboxylic acid (TCA) cycle to produce energy. The observation of a possible upregulation of the TCA cycle in neurodegenerative dementia, inferred from the marginal increase in several intermediates of this cycle in the serum of patients [51,52], also substantiates our hypothesis. Moreover, it is important to highlight that D-glutamate is involved in pathophysiological processes in the brains of patients with AD [45]. This finding suggests that much work needs to be conducted to elucidate the various roles of these D-amino acids in the onset and progression of AD, as recent work has clearly shown that these compounds are distinct.
Investigating the lipidome is very attractive because of its high variability over time, due to the different perturbations experienced by the human body. From an analytical perspective, the most commonly used platforms are targeted LC-MS-based techniques. High-throughput blood lipid profiling has provided insights into the crucial role of these compounds in the pathophysiology of AD. Therefore, we strongly suggest that oleic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, dehydroepiandrosterone sulfate, and cortisol should be monitored in future studies. An adequate daily intake of unsaturated fatty acids, EPA (20:5 n–3) and DHA (22:6 n–3), is officially recommended based on epidemiological results showing the beneficial role of these long-chain PUFAs n–3 in the prevention of cardiovascular and inflammatory diseases [53]. The parent fatty acid ALA (18:3 n–3), found in vegetable oils such as linseed or rapeseed oil, is used by the human body partly as an energy source and partly as a precursor of metabolites. However, the degree of endogenous conversion appears to be unreliable and limited [54]. Most human studies have shown that the conversion of high doses of ALA to EPA occurs, but to a limited extent, whereas the conversion to DHA is severely limited. Indeed, rigorous studies with radioisotopes have shown that in diets rich in saturated fats, the conversion to long-chain metabolites are approximately 6% for EPA and 3.8% for DHA. In contrast, in a diet rich in n–6 PUFA, this conversion was reduced by at least 40%. Therefore, it is reasonable to observe an n–6/n–3 PUFA ratio ≤ 2/3. Restricted conversion to DHA can be critical, as evidence has indicated that this long-chain metabolite has an autonomous function in the brain, retina, and spermatozoa, where it is the most prominent fatty acid [55].
The main limitation of the present study was the small number of participants. Another general problem affecting AD metabolomic and lipidomic studies is the lack of standardization of sampling or analytical methods, which makes it difficult to compare the results between different studies and frequently results in conflicting outcomes. The harmonization of such procedures could help scientists in this fundamental field of investigation. Although some of our findings align well with those reported in other studies [46,55,56,57], suggesting that metabolic dyshomeostasis of specific metabolites is a valuable signature of AD, there is still a significant body of literature utilizing metabolomic approaches, in which the majority of the data obtained differ depending on the patient population selected or the detection procedure applied. Therefore, to gain a greater understanding of the changes in the metabolic pathways in patients with AD, there is a need to increase the number of studies on this topic, bringing all the information together and defining common altered pathways, which might become AD signatures.

4. Materials and Methods

4.1. Participants

The subjects were recruited from the Centre for Research and Training in Medicine of Aging of the University of Molise. All subjects underwent a detailed evaluation including a neurological examination, neuropsychological tests, and routine blood tests. Patients with AD met the National Institute on Aging and the Alzheimer’s Association (NIA-AA) diagnostic criteria for “probable AD, with a documented decline” [58]. They had a Mini-Mental State Examination (MMSE) score of <24 and a Clinical Dementia Rating (CDR) of >0.5. The patient underwent brain imaging to rule out other structural causes of dementia. Subjects were classified as controls when no subjective cognitive complaint was detectable, as well as when neuropsychological tests showed normal cognitive performance with respect to age, sex, and education. The epidemiological factors of all the participants are shown in Table 1.

4.2. Blood Sample Collection

Blood samples were collected between 8:00 and 8:30 a.m. after a 12 h overnight fast, transferred into vacutainer tubes (Becton Dickinson, Milan, Italy), centrifuged at 2000 rpm for 15 min, and stored at −80 °C until they were analyzed.

4.3. Sample Analysis by MxP Quant 500 Assay by Biocrates Life Sciences

All analyses were performed by the Biocrates service using the MxP Quant 500 kit (Biocrates Life Sciences AG, Innsbruck, Austria), including the 630 metabolites.
The kit includes reagents, analytical standards, internal standards, quality control (QC) samples containing expected levels of endogenous analytes, and sample extraction plates.
Briefly, 10 μL of each plasma sample from the patients and controls were extracted in duplicates along the kit QCs and kit calibrator material by using the 96 well plate provided with the kit for sample preparation and quantitative analysis of the metabolite profiles. This device consists of inserts that have been impregnated with internal standards and a predefined sample amount was added to the inserts. After a drying step of 30 min using nitrogen, the derivatization step was performed using a 5% phenyl isothiocyanate (PITC) solution for 1 hour. After another drying step, 300 μL of 5 mM methanolic ammonium acetate was added as the extraction solvent, and the plate was shaken for 30 min, the contents were filtered into a lower sandwich plate by centrifugation at 200× g for 2 min. The sample extracts were diluted for subsequent analysis by mass spectrometry (MS), as specified in the kit user manual.
One extract was analyzed to identify the polar metabolites, including amino acids and related compounds, biogenic amines, fatty acids, bile acids, carbohydrates and related derivatives, hormones, vitamins, indoles and derivatives, nucleobases and their derivatives, using liquid chromatography (LC) coupled with triple quadrupole mass spectrometry (QQQ MS). The other apolar extract was analyzed for lipids including acylcarnitines, phosphatidylcholines (PC, including lyso-PC), sphingomyelins, cholesteryl esters, using flow injection analysis and QQQ MS detection. The concentrations were calculated using appropriate mass spectrometry software (Sciex-Analyst 1.7.2) and a quality control process was conducted with Biocrates MetIDQTM software. Metabolite concentrations, in µM, were provided by Biocrates Life Sciences as an Excel file (Table S1).
Further details on the analytical protocol used for the metabolite profiling can be found in patents EP1897014B1 (https://patentimages.storage.googleapis.com/ee/25/76/af35210654bdc8/EP1897014B1.pdf) and EP1875401B1 (https://patentimages.storage.googleapis.com/78/a1/77/4677d9befb2d3e/EP1875401B1.pdf).

4.4. Data Analysis

Multivariate statistical analysis, metabolite set enrichment analysis (MSEA), and pathway analysis were performed using the freely available online tool MetaboAnalyst 5.0 (www.metaboanalyst.ca) [59]. The volcano plot describes the up- and down regulation of metabolites by using the fold-change (FC) as a ratio between the AD and control subjects, using a criterion of |log2FC| > 0.0. The significant level was selected as the p value threshold < 0.05 transformed as follows: |−log10(p)|. For PLS-DA analysis, the data were normalized using the median, square root transformation, and auto scaled. Only features with VIP > 1.7 were selected. The VIP scores represent the variable’s importance in the PLS-DA model, they summarize the contribution a variable makes to the model in the classification of the two groups: control and AD. Both metabolite set enrichment analysis (MSEA) and pathway analysis were performed using the two modules available in MetaboAnalyst 5.0. The MSEA is used to identify biologically meaningful patterns that are significantly enriched in quantitative metabolomic data. In conventional approaches, metabolites are evaluated individually for their significance under study conditions. Compounds that passed certain significance levels were then combined to determine if any meaningful patterns could be discerned. In contrast, the MSEA directly investigates a set of functionally related metabolites without preselecting compounds based on an arbitrary cut-off threshold. It has the potential to identify subtle but consistent changes among a group of related compounds that may go undetected using conventional approaches. The algorithm selected for the MSEA analysis was quantitative enrichment analysis (QEA). The pathway analysis module combines powerful pathway enrichment analysis results with pathway topology analysis to identify the most relevant pathways involved in the conditions under study. Pathway enrichment analysis uses compound concentration values compared to the compound lists used in the over-representation analysis. The KEGG library was selected for pathway analysis. The significance levels were selected at 0.05 for the p-value and 0.15 for the FDR for both the MSEA and pathway analysis.

5. Conclusions

The targeted mass spectrometry used in this study showed that approximately 25 metabolites were dysregulated in patients with AD compared with the controls. Glycerophospholipids and ceramides were upregulated, while glutamic acid, other phospho-lipids, and sphingolipids were downregulated. Patients with AD also showed dysregulation of at least five pathways involved in the metabolism of polar compounds. To our knowledge, this is the first time that a kit including 630 metabolites was used in the blood of patients with AD. The obtained results could be of help in understanding the metabolic pathways involved in the onset and progression of AD.
Despite some limitations related to the small sample size, this study provides an interesting picture on the use of dysregulations in the lipidomic profile as blood signatures for patients with AD. This paves the way for the possibility of stratifying patients based on changes in metabolic/lipidic blood signatures, thus paving the way for the management of the disease using medications that have been previously used for other pathologies. Indeed, the identification of AD-related blood signatures may be used as an initial diagnostic criterion that can be further analyzed with other examinations, such as PET, neuroimaging, and cerebrospinal fluid analysis of Aβ peptides.

Supplementary Materials

The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24119736/s1.

Author Contributions

Conceptualization, C.M., G.C. and A.D.C.; sample collection and clinical analysis, A.A. and A.D.C.; data analysis, P.R., C.P., G.C., G.F., R.S., R.A. and A.D.C.; writing, reviewing, and editing, C.M., A.A. and A.D.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Italian Ministry of Education, University and Research (PRIN 2017—Grant No. 2017T9JNLT).

Institutional Review Board Statement

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved using the national and international guidelines for human research. The Institutional Review Board (IRB) of the University of Molise approved this study (IRB Prot. n. 16/2020).

Informed Consent Statement

Written informed consent was obtained from all the subjects involved in the study or their caregivers.

Data Availability Statement

Datasets are available upon request from authors. All the raw spectra data are stored by Biocrates Life Sciences AG.

Acknowledgments

We thank Biocrates Life Sciences AG (Innsbruck, Austria) for their technical support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimer’s Dement 2022, 18, 700–789. [Google Scholar] [CrossRef]
  2. Razay, G.; Vreugdenhil, A.; Wilcock, G. The metabolic syndrome and Alzheimer disease. Arch. Neurol. 2007, 64, 93–96. [Google Scholar] [CrossRef] [Green Version]
  3. Litke, R.; Garcharna, L.C.; Jiwani, S.; Neugroschl, J. Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review. Clin. Ther. 2021, 43, 953–965. [Google Scholar] [CrossRef]
  4. Butler, L.M.; Houghton, R.; Abraham, A.; Vassilaki, M.; Durán-Pacheco, G. Comorbidity Trajectories Associated with Alzheimer’s Disease: A Matched Case-Control Study in a United States Claims Database. Front. Neurosci 2021, 15, 749305. [Google Scholar] [CrossRef]
  5. Galvin, J.E.; Chrisphonte, S.; Chang, L.-C. Medical and Social Determinants of Brain Health and Dementia in a Multicultural Community Cohort of Older Adults. J. Alzheimers Dis. 2021, 84, 1563–1576. [Google Scholar] [CrossRef]
  6. Rujeedawa, T.; Carrillo Félez, E.; Clare, I.C.H.; Fortea, J.; Strydom, A.; Rebillat, A.-S.; Coppus, A.; Levin, J.; Zaman, S.H. The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease. J. Clin. Med. 2021, 10, 4582. [Google Scholar] [CrossRef]
  7. Frisardi, V.; Matrone, C.; Street, M.E. Metabolic Syndrome and Autophagy: Focus on HMGB1 Protein. Front. Cell Dev. Biol. 2021, 9, 654913. [Google Scholar] [CrossRef]
  8. Matrone, C.; Iannuzzi, F.; Annunziato, L. The Y682ENPTY687 motif of APP: Progress and insights toward a targeted therapy for Alzheimer’s disease patients. Ageing Res. Rev. 2019, 52, 120–128. [Google Scholar] [CrossRef]
  9. Matrone, C. A new molecular explanation for age-related neurodegeneration: The Tyr682 residue of amyloid precursor protein. Bioessays 2013, 35, 847–852. [Google Scholar] [CrossRef] [Green Version]
  10. Reveglia, P.; Paolillo, C.; Ferretti, G.; De Carlo, A.; Angiolillo, A.; Nasso, R.; Caputo, M.; Matrone, C.; di Costanzo, A.; Corso, G. Challenges in LC-MS-based metabolomics for Alzheimer’s disease early detection: Targeted approaches versus untargeted approaches. Metabolomics 2021, 17, 78. [Google Scholar] [CrossRef]
  11. Fabelo, N.; Martín, V.; Marín, R.; Moreno, D.; Ferrer, I.; Díaz, M. Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer’s disease and facilitates APP/BACE1 interactions. Neurobiol. Aging 2014, 35, 1801–1812. [Google Scholar] [CrossRef] [PubMed]
  12. Frisardi, V.; Panza, F.; Seripa, D.; Farooqui, T.; Farooqui, A.A. Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer’s disease pathology. Prog. Lipid. Res. 2011, 50, 313–330. [Google Scholar] [CrossRef] [PubMed]
  13. Ball, M.J. Frequency of stages of Alzheimer-related lesions in different age categories: Concurrences and cautions. Neurobiol. Aging 1997, 18, 375–376; discussion 389–392. [Google Scholar] [CrossRef]
  14. Braak, H.; Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18, 351–357. [Google Scholar] [CrossRef] [PubMed]
  15. El Gaamouch, F.; Jing, P.; Xia, J.; Cai, D. Alzheimer’s Disease Risk Genes and Lipid Regulators. J. Alzheimer’s Dis. 2016, 53, 15–29. [Google Scholar] [CrossRef] [Green Version]
  16. Cristofano, A.; Sapere, N.; La Marca, G.; Angiolillo, A.; Vitale, M.; Corbi, G.; Scapagnini, G.; Intrieri, M.; Russo, C.; Corso, G.; et al. Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer’s Dementia. PLoS ONE 2016, 11, e0155694. [Google Scholar] [CrossRef] [Green Version]
  17. di Costanzo, A.; Paris, D.; Melck, D.; Angiolillo, A.; Corso, G.; Maniscalco, M.; Motta, A. Blood biomarkers indicate that the preclinical stages of Alzheimer’s disease present overlapping molecular features. Sci. Rep. 2020, 10, 15612. [Google Scholar] [CrossRef]
  18. Corso, G.; Cristofano, A.; Sapere, N.; la Marca, G.; Angiolillo, A.; Vitale, M.; Fratangelo, R.; Lombardi, T.; Porcile, C.; Intrieri, M.; et al. Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia. Dement. Geriatr. Cogn. Dis. Extra 2017, 7, 143–159. [Google Scholar] [CrossRef]
  19. Brereton, R.G.; Lloyd, G.R. Partial least squares discriminant analysis: Taking the magic away. J. Chemom. 2014, 28, 213–225. [Google Scholar] [CrossRef]
  20. Le Stunff, H.; Véret, J.; Kassis, N.; Denom, J.; Meneyrol, K.; Paul, J.L.; Cruciani-Guglielmacci, C.; Magnan, C.; Janel, N. Deciphering the Link Between Hyperhomocysteinemia and Ceramide Metabolism in Alzheimer-Type Neurodegeneration. Front. Neurol. 2019, 10, 807. [Google Scholar] [CrossRef] [Green Version]
  21. Filippov, V.; Song, M.A.; Zhang, K.; Vinters, H.V.; Tung, S.; Kirsch, W.M.; Yang, J.; Duerksen-Hughes, P.J. Increased ceramide in brains with Alzheimer’s and other neurodegenerative diseases. J. Alzheimer’s Dis. 2012, 29, 537–547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Kim, M.; Nevado-Holgado, A.; Whiley, L.; Snowden, S.G.; Soininen, H.; Kloszewska, I.; Mecocci, P.; Tsolaki, M.; Vellas, B.; Thambisetty, M.; et al. Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer’s Disease. J. Alzheimer’s Dis. 2017, 60, 809–817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Pujol-Lereis, L.M. Alteration of Sphingolipids in Biofluids: Implications for Neurodegenerative Diseases. Int. J. Mol. Sci. 2019, 20, 3564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Casañas-Sánchez, V.; Pérez, J.A.; Fabelo, N.; Herrera-Herrera, A.V.; Fernández, C.; Marín, R.; Gonzalez-Montelongo, M.C.; Diaz, M. Addition of docosahexaenoic acid, but not arachidonic acid, activates glutathione and thioredoxin antioxidant systems in murine hippocampal HT22 cells: Potential implications in neuroprotection. J. Neurochem. 2014, 131, 470–483. [Google Scholar] [CrossRef] [PubMed]
  25. Grimm, M.O.; Grimm, H.S.; Hartmann, T. Amyloid beta as a regulator of lipid homeostasis. Trends Mol. Med. 2007, 13, 337–344. [Google Scholar] [CrossRef]
  26. Grimm, M.O.; Grösgen, S.; Riemenschneider, M.; Tanila, H.; Grimm, H.S.; Hartmann, T. From brain to food: Analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer’s disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 2011, 1218, 7713–7722. [Google Scholar] [CrossRef] [PubMed]
  27. Jazvinšćak Jembrek, M.; Hof, P.R.; Šimić, G. Ceramides in Alzheimer’s Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation. Oxid. Med. Cell. Longev. 2015, 2015, 346783. [Google Scholar] [CrossRef] [Green Version]
  28. Law, B.A.; Liao, X.; Moore, K.S.; Southard, A.; Roddy, P.; Ji, R.; Szulc, Z.; Ala Bielawska, A.; Schulze, P.C.; Cowart, L.A. Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes. FASEB J. 2018, 32, 1403–1416. [Google Scholar] [CrossRef] [Green Version]
  29. Hicks, D.A.; Nalivaeva, N.N.; Turner, A.J. Lipid rafts and Alzheimer’s disease: Protein-lipid interactions and perturbation of signaling. Front. Physiol. 2012, 3, 189. [Google Scholar] [CrossRef] [Green Version]
  30. Cheng, H.; Vetrivel, K.S.; Gong, P.; Meckler, X.; Parent, A.; Thinakaran, G. Mechanisms of disease: New therapeutic strategies for Alzheimer’s disease—Targeting APP processing in lipid rafts. Nat. Clin. Pract. Neurol. 2007, 3, 374–382. [Google Scholar] [CrossRef] [Green Version]
  31. Cordy, J.M.; Hooper, N.M.; Turner, A.J. The involvement of lipid rafts in Alzheimer’s disease. Mol. Membr. Biol. 2006, 23, 111–122. [Google Scholar] [CrossRef]
  32. Allinson, T.M.; Parkin, E.T.; Condon, T.P.; Schwager, S.L.; Sturrock, E.D.; Turner, A.J.; Hooper, N.M. The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur. J. Biochem. 2004, 271, 2539–2547. [Google Scholar] [CrossRef] [PubMed]
  33. Ehehalt, R.; Keller, P.; Haass, C.; Thiele, C.; Simons, K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160, 113–123. [Google Scholar] [CrossRef]
  34. Grimm, M.O.; Haupenthal, V.J.; Rothhaar, T.L.; Zimmer, V.C.; Grösgen, S.; Hundsdörfer, B.; Lehmann, J.; Grimm, H.S.; Hartmann, T. Effect of Different Phospholipids on α-Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer’s Disease. Int. J. Mol. Sci. 2013, 14, 5879–5898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Grimm, M.O.; Mett, J.; Grimm, H.S.; Hartmann, T. APP Function and Lipids: A Bidirectional Link. Front. Mol. Neurosci. 2017, 10, 63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Rimm, M.O.; Rothhaar, T.L.; Hartmann, T. The role of APP proteolytic processing in lipid metabolism. Exp. Brain Res. 2012, 217, 365–375. [Google Scholar]
  37. Shimohama, S.; Tanino, H.; Sumida, Y.; Tsuda, J.; Fujimoto, S. Alteration of myo-inositol monophosphatase in Alzheimer’s disease brains. Neurosci. Lett 1998, 245, 159–162. [Google Scholar] [CrossRef]
  38. Lee, H.N.; Sim, K.M.; Kim, H.; Ju, J.; Pae, A.N.; Park, J.B.; Ryu, H.; Seong, J. Aβ modulates actin cytoskeleton via SHIP2-mediated phosphoinositide metabolism. Sci. Rep. 2019, 9, 15557. [Google Scholar] [CrossRef] [Green Version]
  39. Matrone, C.; Petrillo, F.; Nasso, R.; Ferretti, G. Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions. Int. J. Mol. Sci. 2020, 21, 4444. [Google Scholar] [CrossRef]
  40. Arcaro, A.; Aubert, M.; del Hierro, M.E.E.; Khanzada, U.K.; Angelidou, S.; Tetley, T.D.; Bittermann, A.G.; Frame, M.C.; Seckl, M.J. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal 2007, 19, 1081–1092. [Google Scholar] [CrossRef]
  41. Iannuzzi, F.; Sirabella, R.; Canu, N.; Maier, T.J.; Annunziato, L.; Matrone, C. Fyn Tyrosine Kinase Elicits Amyloid Precursor Protein Tyr682 Phosphorylation in Neurons from Alzheimer’s Disease Patients. Cells 2020, 9, 1807. [Google Scholar] [CrossRef]
  42. Bhaskar, K.; Yen, S.H.; Lee, G. Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 2005, 280, 35119–35125. [Google Scholar] [CrossRef] [Green Version]
  43. Bordji, K.; Becerril-Ortega, J.; Nicole, O.; Buisson, A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ß production. J. Neurosci. 2010, 30, 15927–15942. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Bukke, V.N.; Archana, M.; Villani, R.; Romano, A.D.; Wawrzyniak, A.; Balawender, K.; Orkisz, S.; Beggiato, S.; Serviddio, G.; Cassano, T. The Dual Role of Glutamatergic Neurotransmission in Alzheimer’s Disease: From Pathophysiology to Pharmacotherapy. Int. J. Mol. Sci. 2020, 21, 7452. [Google Scholar] [CrossRef]
  45. Seckler, J.M.; Lewis, S.J. Advances in D-Amino Acids in Neurological Research. Int. J. Mol. Sci. 2020, 21, 7325. [Google Scholar] [CrossRef]
  46. Toledo, J.B.; Arnold, M.; Kastenmüller, G.; Chang, R.; Baillie, R.A.; Han, X.; Thambisetty, M.; Tenenbaum, J.D.; Suhre, K.; Thompson, J.W.; et al. Metabolic network failures in Alzheimer’s disease: A biochemical road map. Alzheimer’s Dement. 2017, 13, 965–984. [Google Scholar] [CrossRef]
  47. Yashiro, K.; Philpot, B.D. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008, 55, 1081–1094. [Google Scholar] [CrossRef] [Green Version]
  48. Mattson, M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N. Y. Acad. Sci. 2008, 1144, 97–112. [Google Scholar] [CrossRef] [Green Version]
  49. Zeydan, B.; Deelchand, D.K.; Tosakulwong, N.; Lesnick, T.G.; Kantarci, O.H.; Machulda, M.M.; Knopman, D.S.; Lowe, V.J.; Clifford, R.J.J.; Petersen, R.C.; et al. Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. J. Neuroimaging 2017, 27, 630–636. [Google Scholar] [CrossRef] [PubMed]
  50. Lin, C.H.; Yang, H.T.; Chiu, C.C.; Lane, H.Y. Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Sci. Rep. 2017, 7, 14849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Sang, C.; Philbert, S.A.; Hartland, D.; Unwin, R.; Dowsey, A.W.; Xu, J.; Cooper, G.J. Coenzyme A-Dependent Tricarboxylic Acid Cycle Enzymes Are Decreased in Alzheimer’s Disease Consistent with Cerebral Pantothenate Deficiency. Front. Aging Neurosci. 2022, 14, 893159. [Google Scholar] [CrossRef]
  52. Cleland, N.R.W.; Al-Juboori, S.I.; Dobrinskikh, E.; Bruce, K.D. Altered substrate metabolism in neurodegenerative disease: New insights from metabolic imaging. J. Neuroinflammation 2021, 18, 248. [Google Scholar] [CrossRef] [PubMed]
  53. van Dael, P. Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations. Nutr. Res. Pract. 2021, 15, 137–159. [Google Scholar] [CrossRef] [PubMed]
  54. Gerster, H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int. J. Vitam. Nutr. Res. 1998, 68, 159–173. [Google Scholar]
  55. Kalecký, K.; German, D.C.; Montillo, A.A.; Bottiglieri, T. Targeted Metabolomic Analysis in Alzheimer’s Disease Plasma and Brain Tissue in Non-Hispanic Whites. J. Alzheimer’s Dis. 2022, 86, 1875–1895. [Google Scholar] [CrossRef] [PubMed]
  56. Casanova, R.; Varma, S.; Simpson, B.; Kim, M.; An, Y.; Saldana, S.; Riveros, C.; Moscato, P.; Griswold, M.; Sonntag, D.; et al. Blood metabolite markers of preclinical Alzheimer’s disease in two longitudinally followed cohorts of older individuals. Alzheimer’s Dement. 2016, 12, 815–822. [Google Scholar] [CrossRef] [Green Version]
  57. Varma, V.R.; Oommen, A.M.; Varma, S.; Casanova, R.; An, Y.; Andrews, R.M.; O’Brien, R.; Pletnikova, O.; Troncoso, J.C.; Toledo, J.; et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med. 2018, 15, e1002482. [Google Scholar] [CrossRef]
  58. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack Jr, C.R.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011, 7, 263–269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Pang, Z.; Chong, J.; Zhou, G.; de Lima Morais, D.A.; Chang, L.; Barrette, M.; Gauthier, C.; Jacques, P.E.; Li, S.; Xia, J. MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021, 49, W388–W396. [Google Scholar] [CrossRef]
Ijms 24 09736 g001 550
Figure 1. (a) 3D score plot of the three selected PCs for AD (red) and controls (green). The corresponding percentages of the variance (%) are reported in parentheses. (b) Important features identified by the PLS-DA. The boxes on the right indicate the relative concentrations of the metabolites in the AD and control. (c) Volcano plot with fold-change threshold (x) 1 and t-test threshold (y) of 0.05. The red circles represent features above the threshold. Note that fold changes log2 (FC) and p values log10 (p) were log transformed. On the (x) axis, the further the position from (0,0), the more significant the feature.
Figure 1. (a) 3D score plot of the three selected PCs for AD (red) and controls (green). The corresponding percentages of the variance (%) are reported in parentheses. (b) Important features identified by the PLS-DA. The boxes on the right indicate the relative concentrations of the metabolites in the AD and control. (c) Volcano plot with fold-change threshold (x) 1 and t-test threshold (y) of 0.05. The red circles represent features above the threshold. Note that fold changes log2 (FC) and p values log10 (p) were log transformed. On the (x) axis, the further the position from (0,0), the more significant the feature.
Ijms 24 09736 g001
Ijms 24 09736 g002 550
Figure 2. Quantitative enrichment analysis (QEA). The color of the bar refers to the p-value. Red bars indicate more significant enrichment.
Figure 2. Quantitative enrichment analysis (QEA). The color of the bar refers to the p-value. Red bars indicate more significant enrichment.
Ijms 24 09736 g002
Ijms 24 09736 g003 550
Figure 3. Summary of the pathway analysis. The color of the dot is the p-value; the redder the point, the more significant is the enrichment. The size of the spot represents the number of metabolite hits in the study.
Figure 3. Summary of the pathway analysis. The color of the dot is the p-value; the redder the point, the more significant is the enrichment. The size of the spot represents the number of metabolite hits in the study.
Ijms 24 09736 g003
Table
Table 1. Epidemiological factors and disease status of the study participants. Healthy volunteers (controls, n = 20) and Alzheimer’s patients (AD, n = 20).
Table 1. Epidemiological factors and disease status of the study participants. Healthy volunteers (controls, n = 20) and Alzheimer’s patients (AD, n = 20).
Controls (n = 20)AD (n = 20)p-Value
Age (mean ± SD)76.85 ± 7.980.85 ± 5.30.075
Gender (n %): 1
Male10 (50%)8 (40%)
Female10 (50%)12 (60%)
Education (mean of years ± SD)11.9 ± 3.78.35 ± 3.40.003406 *
MMSE score (mean ± SD)29.83 ± 1.220.95 ± 2.92.86 × 10−12 *
GDS (mean ± SD)3.05 ± 2.95.38 ± 3.50.060041
BMI (mean ± SD)27.08 ± 1.625.3 ± 3.90.108194
Comorbidities (n, %):
Alcohol12 (60%)11 (55%)0.749
Smoker12 (60%)6 (30%)0–056
Dyslipidaemia6 (30%)3 (15%)0.255
Diabetes3 (15%)3 (15%)1
Hypertension9 (45%)6 (30%)0.327
TIA/ischemia1 (5%)1 (5%)1
Cardiac ischemia0 (0%)2 (10%)0.167
Prior tumors4 (20%)2 (10%)0.375
Drugs:
Antihypertension9 (45%)6 (30%)0.327
Hypoglycaemic3 (15%)3 (15%)1
Hypolipidemic6 (30%)3 (15%)0.255
Antiplatelet1 (5%)3 (15%)0.197
Antiacid2 (10%)4 (20%)0.375
MMSE: Mini-Mental State Examination; GDS: geriatric depression scale; BMI: body mass index. * Statistically significant.
Table
Table 2. Down/upregulated metabolites for comparison between AD and controls.
Table 2. Down/upregulated metabolites for comparison between AD and controls.
CompoundClassTypep-ValueFClog2(FC)VIP
Hydroxysphingo-myelin C22:1sphingolipidDown0.00080.7728−0.37182.775
Hydroxysphingo-myelin C24:2sphingolipidDown0.00240.7779−0.36242.552
L-Glutamic acidamino acidDown0.00430.6142−0.70322.419
Gamma-Aminobutyric acidamino acidDown0.00890.8282−0.2722.231
Ceramide (d18:1/24:1)lipidUp0.01331.18140.24052.123
CE (18:2(9Z,12Z))lipidDown0.01420.8273−0.27352.103
L-Aspartic acidamino acidDown0.01640.8039−0.3152.063
Hydroxysphingo-myelin C22:2sphingolipidDown0.01880.8346−0.26082.023
SM(d18:1/26:0)sphingolipidDown0.01930.7856−0.34822.015
L-2-Hydroxyglutaric acidorganic acidDown0.02070.8858−0.1751.993
SM (d18:1/24:0)sphingolipidDown0.02290.8416−0.24881.963
Lysophosphatidyl-choline C14:1phospholipidDown0.02380.8017−0.3191.951
Homo-L-arginineamino acidDown0.02960.7429−0.42871.883
Octadecadienoatefatty acid
derivative		Down0.03210.6734−0.57051.856
Phosphatidyl-choline aa C28:1phospholipidDown0.03550.8997−0.15241.823
L-Carnitineamino acidDown0.04380.8435−0.24561.752
PC aa C40:3phospholipidUp0.04861.26410.33811.716
Legend: CE = cholesteryl ester; SM = sphingomyelin; PC = phosphatidylcholine.
Table
Table 3. Table summarizing the QEA results. FDR: false discovery rate control.
Table 3. Table summarizing the QEA results. FDR: false discovery rate control.
PathwayTotal
Metabolites		Hits
Metabolites		Raw pFDR
Biosynthesis of
unsaturated fatty acids		3640.1760.482
Steroid hormone biosynthesis8520.2380.482
Fatty acid degradation3910.3050.482
Primary bile acid biosynthesis4640.3210.482
Lysine degradation2510.6840.777
Arachidonic acid metabolism3610.7770.777
Table
Table 4. Altered metabolic pathways (raw p < 0. 05, FDR < 0.15) and altered metabolites in different pathways.
Table 4. Altered metabolic pathways (raw p < 0. 05, FDR < 0.15) and altered metabolites in different pathways.
PathwayRaw pFDRTotal
Metabolites in the Pathway		Hits MetabolitesAltered MetabolitesType
Butanoate
metabolism		0.00040.02154-Aminobutanoate
L-Glutamate		L-GlutamateDown
Histidine
metabolism		0.00700.1316L-Glutamate
L-Histidine
N(pi)-Methyl-L-histidine
L-Aspartate		L-Glutamate
L-Aspartate		Down
Down
Alanine aspartate and glutamate
metabolism		0.01350.1328L-Aspartate
L-Asparagine
L-Alanine
L-Glutamate
4-Aminobutanoate
L-Glutamine		4-Aminobutanoate L-GlutamateDown
Down
Arginine and
proline
metabolism		0.01610.1338L-Arginine
4-Aminobutanoate
Putrescine
Hydroxyproline
L-Proline
L-Glutamate
L-Ornithine		4-Aminobutanoate L-GlutamateDown
Down
Nicotinate and
nicotinamide
metabolism		0.01640.1315L-AspartateL-AspartateDown
Porphyrin and chlorophyll
metabolism		0.01730.1330Glycine
L-Glutamate		L-GlutamateDown
D-Glutamine and D-glutamate
metabolism		0.02530.146L-Glutamate
L-Glutamine		L-GlutamateDown
Nitrogen
metabolism		0.02530.146L-Glutamate
L-Glutamine		L-GlutamateDown
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Reveglia, P.; Paolillo, C.; Angiolillo, A.; Ferretti, G.; Angelico, R.; Sirabella, R.; Corso, G.; Matrone, C.; Di Costanzo, A. A Targeted Mass Spectrometry Approach to Identify Peripheral Changes in Metabolic Pathways of Patients with Alzheimer’s Disease. Int. J. Mol. Sci. 2023, 24, 9736. https://doi.org/10.3390/ijms24119736

AMA Style

Reveglia P, Paolillo C, Angiolillo A, Ferretti G, Angelico R, Sirabella R, Corso G, Matrone C, Di Costanzo A. A Targeted Mass Spectrometry Approach to Identify Peripheral Changes in Metabolic Pathways of Patients with Alzheimer’s Disease. International Journal of Molecular Sciences. 2023; 24(11):9736. https://doi.org/10.3390/ijms24119736

Chicago/Turabian Style

Reveglia, Pierluigi, Carmela Paolillo, Antonella Angiolillo, Gabriella Ferretti, Ruggero Angelico, Rossana Sirabella, Gaetano Corso, Carmela Matrone, and Alfonso Di Costanzo. 2023. "A Targeted Mass Spectrometry Approach to Identify Peripheral Changes in Metabolic Pathways of Patients with Alzheimer’s Disease" International Journal of Molecular Sciences 24, no. 11: 9736. https://doi.org/10.3390/ijms24119736

APA Style

Reveglia, P., Paolillo, C., Angiolillo, A., Ferretti, G., Angelico, R., Sirabella, R., Corso, G., Matrone, C., & Di Costanzo, A. (2023). A Targeted Mass Spectrometry Approach to Identify Peripheral Changes in Metabolic Pathways of Patients with Alzheimer’s Disease. International Journal of Molecular Sciences, 24(11), 9736. https://doi.org/10.3390/ijms24119736

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop